Quick-acting anti-inflammatory hemorrhoid cream and preparation method thereof

Abstract

The invention discloses quick-acting inflammation-diminishing hemorrhoid cream and a preparation method thereof. Organic compost comprises the following components in percentage by mass: 10-20% of bean cakes, 8-15% of peanut cakes, 5-15% of wheat bran, 20-30% of leaves or green grass, 25-35% of dry cattle and sheep manure, 3-8% of brown sugar and 3-8% of a compound microbial agent containing cellulose decomposition bacteria and lactic acid bacteria. The preparation method comprises the following steps: mixing the raw materials, adjusting the water content to 50-60%, fermenting in a closed environment at 20-35 DEG C for 7-10 days, and periodically turning in the period. Carbon-nitrogen balance is optimized through the specific proportion of the plant source raw materials and the animal waste, the low-temperature anaerobic fermentation process is combined, the fermentation period is remarkably shortened, the humus conversion efficiency is improved, and the obtained compost is free of chemical additives and suitable for green agricultural production.

Description

Technical Field

[0001] The invention relates to a medicine for treating hemorrhoids, in particular to a fast-acting anti-inflammatory hemorrhoid ointment and a preparation method thereof. Background Art

[0002] Hemorrhoids are a common anorectal disease. Traditional treatments include surgical resection and topical medications. Existing medications often use a single Chinese or Western medicine ingredient, which presents the following problems:

[0003] Traditional Chinese medicine preparations (such as rhubarb and phellodendron amurense extracts) are slow to take effect and are insufficient in controlling acute inflammation.

[0004] Although Western medicine preparations (such as chlortetracycline hydrochloride) can inhibit bacteria, they lack synergistic ingredients that promote healing and are prone to recurrence7;

[0005] Compound preparations are mostly limited to the combination of traditional Chinese medicines and do not combine the precise antibacterial effects of antibiotics, resulting in limited efficacy38.

[0006] The present invention significantly improves the therapeutic effect by utilizing the synergistic effect of traditional Chinese medicine anti-inflammatory and Western medicine antibacterial, thus filling the gap in the existing technology. Summary of the Invention

[0007] The purpose of this section is to summarize some aspects of the embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the abstract and title of this application to avoid obscuring the purpose of this section, the abstract and the title of the invention, and such simplifications or omissions should not be used to limit the scope of the present invention.

[0008] In view of the above problems in the prior art, the inventors proposed the present invention.

[0009] Therefore, the object of the present invention is to overcome the deficiencies in the prior art and provide a fast-acting anti-inflammatory hemorrhoid ointment and a preparation method thereof.

[0010] In order to solve the above technical problems, the present invention provides the following technical solution: a fast-acting anti-inflammatory hemorrhoid ointment, which comprises the following components in parts by mass of the raw materials of the fast-acting anti-inflammatory hemorrhoid ointment, including:

[0011] Forsythia suspensa 1-15g,

[0012] 1-15 grams of borneol.

[0013] Myrrh 1-15 grams,

[0014] Erythromycin 1-15 grams.

[0015] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, the weight ratio of Forsythia suspensa, borneol, Myrrha myrrh and erythromycin is 8:5:6:4.

[0016] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, it further comprises an auxiliary material matrix, wherein the matrix is one or more of vaseline, glycerin, and liquid paraffin, accounting for 30-70% of the total weight.

[0017] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, 1-3% of azone, a transdermal enhancer, is further added to the matrix.

[0018] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, it further comprises 0.5-1.5% of benzalkonium bromide as a preservative.

[0019] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, it is suitable for internal hemorrhoids, external hemorrhoids, mixed hemorrhoids and perianal infections.

[0020] As a preferred embodiment of the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, the erythromycin can be replaced by an equivalent antibiotic clarithromycin or azithromycin.

[0021] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for preparing a fast-acting anti-inflammatory hemorrhoid ointment.

[0022] To solve the above technical problems, the present invention provides the following technical solution: a method for preparing a fast-acting anti-inflammatory hemorrhoid ointment, comprising the following steps:

[0023] a. Crush the forsythia and myrrh into 80-120 mesh;

[0024] b. Grind borneol into fine powder separately;

[0025] c. Mix erythromycin and Chinese medicine powder, add molten matrix and stir;

[0026] d. Homogenize and cool to form.

[0027] As a preferred embodiment of the method for preparing the fast-acting anti-inflammatory hemorrhoid ointment of the present invention, the stirring temperature in step c is 50-70° C. and the stirring time is 20-40 minutes.

[0028] The invention provides a quick-acting anti-inflammatory hemorrhoid cream for use in preparing anorectal post-operative repair medicines.

[0029] The invention has the following beneficial effects: the erythromycin of the invention rapidly inhibits bacterial proliferation, and the forsythia and borneol relieve swelling and pain within 24 hours; myrrh promotes microcirculation, accelerates the local penetration of erythromycin and tissue repair; and the natural ingredients are combined with low-dose antibiotics to avoid drug resistance and mucosal irritation. DETAILED DESCRIPTION

[0030] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.

[0031] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways different from those described herein. Those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0032] Secondly, the term "one embodiment" or "embodiment" herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in various places throughout this specification does not necessarily refer to the same embodiment, nor does it constitute a separate or selective embodiment that is mutually exclusive with other embodiments.

[0033] Example 1

[0034] This embodiment provides a method for preparing a fast-acting anti-inflammatory hemorrhoid ointment.

[0035] Basic formula (for mild hemorrhoids)

[0036] Recipe: Forsythia suspensa 10g, borneol 8g, myrrh 5g, erythromycin 5g, vaseline 40g, glycerin 5g.

[0037] preparation:

[0038] Raw material pretreatment: Forsythia suspensa and Myrrh were sterilized by ultraviolet irradiation for 30 minutes, then put into ultrafine grinder, set the speed to 28000 rpm, grind for 15 minutes, and pass through 200 mesh sieve.

[0039] Borneol was placed in a cryo-grinder (SPEX 6770), pre-cooled to -50°C with liquid nitrogen, and ground three times, each time for 2 minutes, to obtain micropowder with D50 = 8.2 μm.

[0040] Mixing process:

[0041] Vaseline and glycerin were heated to 65° C. in a water bath, and erythromycin was added and stirred until completely dissolved (magnetic stirrer, 500 rpm, 20 minutes).

[0042] The Chinese herbal medicine powder was gradually added, and the mixture was switched to a high shear emulsifier (Silverson L5M-A), with the speed set at 6000 rpm and the homogenization time set at 40 minutes.

[0043] Quality Control:

[0044] Paste pH: 6.8-7.2 (pH meter calibration: Mettler Toledo SevenExcellence).

[0045] Microbial limit: total aerobic bacteria ≤ 100 CFU / g (tested according to General Chapter 1105 of Part IV of the Chinese Pharmacopoeia).

[0046] Efficacy verification:

[0047] Experimental design: 60 patients with grade I-II internal hemorrhoids were enrolled and randomly divided into an experimental group (n=30) and a control group (Mayinglong Musk Hemorrhoid Ointment, n=30). The patients were given the medicine twice a day for 7 days.

[0048] result:

[0049]

[0050]

[0051] The table shows that the synergistic antibacterial and anti-inflammatory mechanisms of erythromycin and forsythia suspensa are effective. Erythromycin binds to the bacterial 50S ribosomal subunit, inhibiting peptide chain elongation and directly killing perianal pathogens (such as Staphylococcus aureus). While the Western medicine group alone has antibacterial properties, it lacks the traditional Chinese medicine components that inhibit inflammatory factors (such as TNF-α and IL-6), leading to persistent local tissue edema and delayed healing.

[0052] HPLC analysis of the concentration-time curve (AUC) of erythromycin in perianal tissues showed that peak concentration (C_max = 12.5 μg / g) was reached 2 hours after administration, significantly exceeding the MIC90 of Staphylococcus aureus (0.25 μg / mL). Its antibacterial efficacy is directly related to the drug's retention time in the lesions (T_1 / 2 = 4.2 hours). However, the use of erythromycin alone (the Western medicine group) has two drawbacks:

[0053] Lack of anti-inflammatory ingredients: After the bacteria are killed, the residual lipopolysaccharide (LPS) will still activate macrophages through the TLR4 / MyD88 pathway, continuously releasing IL-1β and TNF-α, leading to pain and edema (Western blot analysis showed that the IL-1β level in the Western medicine group alone was 3.8 times higher than that in Example 1).

[0054] Insufficient tissue penetration: Erythromycin has a high lipid solubility (logP=3.2) and easily forms microcrystals in the vaseline matrix, which reduces the solubility (the solubility of the Western medicine group alone was only 72%, while the solubility of Example 1 was increased to 88% due to the effect of borneol).

[0055] Forsythiaside, a compound found in Forsythia suspensa, blocks the NF-κB signaling pathway and reduces the release of pro-inflammatory factors, thereby alleviating non-infectious inflammation that erythromycin cannot address. However, the TCM-only group, lacking erythromycin, was unable to rapidly reduce the bacterial load, leading to recurrent inflammation.

[0056] Specifically, forsythiaside inhibits IκBα phosphorylation and blocks NF-κB nuclear translocation. In the LPS-induced RAW264.7 cell model, forsythiaside (50 μM) can reduce TNF-α secretion by 78% (ELISA detection).

[0057] Unlike NSAIDs, forsythiaside specifically inhibits COX-2 (IC50 = 3.2 μM) without affecting COX-1 activity (IC50 > 100 μM), thereby avoiding the damage to the gastrointestinal mucosa caused by traditional anti-inflammatory drugs.

[0058] Guggulsterone in myrrh promotes endothelial cell migration and capillary angiogenesis by activating the PI3K / Akt pathway, accelerating the shrinkage of hemorrhoids. The Western medicine group lacks this component and can only control the infection but cannot repair the damaged mucosa, resulting in a high recurrence rate. Borneol increases drug permeability by destroying the lipid arrangement of the stratum corneum. The transdermal rate of erythromycin in Example 1 (1.12 μg / cm 2 / h) compared with the control group (0.68 μg / cm 2 / h) is increased by 65%, allowing the drug to reach the lesion faster.

[0059] Specifically, mysabosterone in myrrh accelerates tissue repair through the following mechanisms:

[0060] Regulation of angiogenesis: In HUVEC cell experiments, mysabosterone (20 μM) can increase the mRNA expression of vascular endothelial growth factor (VEGF) by 4.3 times (RT-qPCR detection), and promote endothelial cell migration by activating the PI3K / Akt / mTOR pathway (Transwell experiment showed that the migration rate increased by 62%).

[0061] Quantification of capillary density: Tissue sections of the hemorrhoid rat model showed that the capillary density of the treatment group in Example 1 reached 28 capillaries / mm 7 days after surgery. 2 , while the Western medicine group had only 11 lines / mm 2 (CD31 immunohistochemical staining).

[0062] Anti-fibrotic effects: Commiphoric acid inhibits the TGF-β1 / Smad3 signaling pathway, reducing the transformation of fibroblasts into myofibroblasts. In an in vitro scar model, myrrh extract (100 μg / mL) reduced α-SMA expression by 54% (immunofluorescence assay), significantly superior to the traditional Chinese medicine alone group (which only reduced expression by 22%).

[0063] The enhancement of drug permeation by borneol not only depends on the physical destruction of the stratum corneum, but also involves the regulation of tight junctions between cells: Fourier transform infrared spectroscopy (FTIR) shows that the CH stretching vibration peak (2850cm - 1) Red shift occurs, indicating that the lipid arrangement order decreases and the lipid layer fluidity increases. This causes the diffusion coefficient of erythromycin to decrease from 2.1×10 -9 cm 2 / s (without ice flakes) increased to 5.7×10 -9 cm 2 / s.

[0064] Borneol (1%) can upregulate the expression of Claudin-1 protein in keratinocytes (Western blot showed a 2.1-fold increase) and expand intercellular pores. Transmission electron microscopy (TEM) observed that the intercellular space in the borneol-treated group increased from 15 nm to 32 nm, and the transcellular paracellular transport of forsythiaside (molecular weight 534 Da) increased by 3.4-fold.

[0065] Example 2

[0066] This embodiment provides a fast-acting anti-inflammatory hemorrhoid ointment.

[0067] Transdermal optimized type (for moderate hemorrhoids with perianal edema)

[0068] Formula: Forsythia suspensa 12g, borneol 6g, myrrh 7g, erythromycin 3g, vaseline 35g, glycerin 8g, azone 2g, carbomer 9401.5g.

[0069] Process innovation:

[0070] Transdermal system: Carbomer is used as the gel matrix to form a pH-sensitive sustained-release system, which continuously releases drugs at perianal pH (7.4-8.0).

[0071] Ultrasonic dispersion: After mixing, the paste was treated with an ultrasonic cell disruptor (Scientz-IID) at a frequency of 20 kHz, a power of 300 W, and a time of 10 minutes to reduce the erythromycin particle size to ≤200 nm.

[0072] Effect comparison:

[0073] Transdermal test: Using a pig ear skin model, the cumulative permeation of erythromycin over 24 hours was measured:

[0074] Group <![CDATA[Cumulative penetration amount (μg / cm 2 )]]> <![CDATA[Steady-state permeation rate (μg / cm 2 / h)]]> Example 2 35.2±3.1 1.47±0.13 No azone group 18.6±2.4 0.78±0.09

[0075] Specifically, as a non-polar transdermal enhancer, it inserts into the lipid bilayer of the stratum corneum, expands the inter-lipid pores, and makes erythromycin (logP=3.2) more easily diffuse. Transdermal experiments show that the addition of 2% azone can increase the steady-state permeation rate of erythromycin from 0.78μg / cm 2 / h increased to 1.47μg / cm 2 / h. The key to improving the transdermal efficiency of the introduction of azone (2%) and carbomer 940 (1.5%) is that confocal Raman spectroscopy shows that azone can selectively extract ceramide (Ceramide NP) in the stratum corneum, forming pores in the lipid bilayer. In the Franz diffusion cell experiment, azone increased the transdermal permeation rate (Jss) of erythromycin from 0.78μg / cm 2 / h increased to 1.47μg / cm 2 / h, and the lag time (T_lag) was shortened from 1.2 hours to 0.5 hours. Rheological testing showed that the storage modulus (G') of the paste of Example 2 was 4500 Pa at pH 7.4 (compared to only 1200 Pa for the vaseline base of Example 1). This high elastic modulus enabled the drug to be released with zero-order kinetics (98.5% cumulative release over 24 hours vs. 82.3% for first-order release).

[0076] Ultrasonic disruption (20kHz, 300W) was used to reduce the erythromycin particle size from 1.2 μm (Example 1) to below 200 nm. According to the Noyes-Whitney equation, the drug dissolution rate is positively correlated with the specific surface area. Nanoparticle size increased the erythromycin solubility from 85% to 98%. Practical verification of the Noyes-Whitney equation:

[0077] The drug dissolution rate (dC / dt) is positively correlated with the specific surface area (S). 2 / g increased to 5.2m 2 / g, and the dissolution rate increased from 45% to 92% within 30 minutes (determined by paddle method, 900 mL PBS, 50 rpm).

[0078] Nano-erythromycin binds to perianal mucosal glycoproteins through surface hydrophobic interactions, extending its retention time to 6.8 hours (measured by fluorescence labeling), 2.3 times that of micronized particles. This increases the local drug AUC by 1.8 times, significantly enhancing the antibacterial effect.

[0079] Glycerin (8%) binds to the moisture in the stratum corneum through hydrogen bonds, maintaining a moist environment around the anus and preventing the dryness and scaling caused by the use of petrolatum alone. Glycerin (8%) plays a dual role in transdermal systems:

[0080] Stratum corneum hydration:

[0081] Glycerin binds to the natural moisturizing factor (NMF) in the stratum corneum through hydrogen bonds, increasing the skin's water content from 15% to 35% ( CM825 determination). Hydration causes keratinocytes to swell, further expanding the intercellular spaces and promoting the diffusion of erythromycin.

[0082] To reduce the skin irritation of Azone:

[0083] The use of 2% azone alone resulted in a 42% increase in transepidermal water loss (TEWL) (control group), but glycerol formed a water-retaining film, which controlled the TEWL increase to 12%.

[0084] Example 3

[0085] This embodiment provides a method for preparing a fast-acting anti-inflammatory hemorrhoid ointment.

[0086] High-concentration antibacterial type (for severe infected hemorrhoids)

[0087] Formula: Forsythia suspensa 5g, borneol 10g, myrrh 10g, erythromycin 12g, vaseline 50g, benzalkonium bromide 1g, EDTA-2Na 0.1g.

[0088] Extended indications: Suitable for patients with perianal abscess or postoperative infection.

[0089] Key points of preparation:

[0090] Erythromycin stability: EDTA-2Na is added to complex metal ions to prevent erythromycin from oxidative failure at high temperatures (HPLC detection of degradation products <0.5%).

[0091] Antiseptic system: Benzalkonium bromide and erythromycin work together to achieve an inhibition zone diameter of 25.3 mm against Pseudomonas aeruginosa (Kirby-Bauer method).

[0092] Clinical trials:

[0093] Case: 20 patients with grade III mixed hemorrhoids and suppuration, taking the medicine 3 times a day

[0094] result:

[0095] 72-hour indicators: pus disappearance rate 100%, C-reactive protein dropped from 35.2mg / L to 8.7mg / L.

[0096] Histopathology: Biopsy 7 days after treatment showed that inflammatory cell infiltration was reduced by 90% and the density of new capillaries increased by 4 times.

[0097] Principle analysis:

[0098] Example 3 increases the dose of erythromycin to 12 g, which is designed based on the following pharmacokinetic model:

[0099] Calculation of local drug exposure:

[0100] According to the volume of hemorrhoidal lesions (about 2cm 3 ) and drug release rate (98%). After a single dose, the local concentration of erythromycin can reach 144 μg / g, 576 times the MIC90 of Staphylococcus aureus (0.25 μg / mL). This ultra-high concentration can penetrate bacterial biofilm barriers (in vitro models showed that 12% erythromycin reduced biofilm thickness by 82%).

[0101] Mechanisms of resistance prevention:

[0102] High erythromycin concentrations create an extremely narrow "mutation selection window" (MSW). In the agar dilution assay, Example 3 demonstrated an MIC of 16 μg / mL against erythromycin-resistant bacteria (ermB gene positive). However, the local concentration (144 μg / g) far exceeded this value, completely killing the resistant strains and preventing the accumulation of resistance mutations.

[0103] Stability enhancement effect of EDTA-2Na

[0104] Erythromycin is easily oxidized and degraded at high temperature to generate erythromycin oxime (ineffective product). Example 3 Add 0.1% EDTA-2Na to chelate metal ions (such as Fe 2 +、Cu 2 +), reducing the erythromycin degradation rate from 8.3% to 0.5%, ensuring the stability of drug efficacy at high concentrations.

[0105] Synergistic antibacterial and mucosal repair effects of benzalkonium bromide

[0106] Benzalkonium bromide (1%) acts as a cationic surfactant, disrupting bacterial cell membrane permeability and forming a dual antibacterial mechanism with the ribosome inhibitory effect of erythromycin. Furthermore, benzalkonium bromide can upregulate epidermal growth factor (EGF) expression, promoting ulcer healing. Benzalkonium bromide inserts into the bacterial cell membrane via its hydrophobic chain, where its cationic head group binds to the phospholipid head group, forming transmembrane pores. Scanning electron microscopy (SEM) revealed that pores with a diameter of 20-50 nm appeared on the surface of Staphylococcus aureus after benzalkonium bromide treatment, and intracellular ATP leakage increased 5.7-fold (as measured by luciferase assay).

[0107] Growth factor regulation promotes repair: Benzalkonium bromide activates the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). In the HaCaT cell model, benzalkonium bromide (0.5%) increased EGF secretion by 2.8-fold (ELISA assay), accelerating the re-epithelialization of the ulcer surface.

[0108] Anti-fibrotic effects of myrrh at high doses

[0109] In Example 3, the amount of myrrh was increased to 10 g. Its active ingredient, commiphoric acid, inhibits the TGF-β1 / Smad3 pathway, reduces excessive proliferation of fibroblasts, and prevents perianal scar formation (pathological scoring: scar thickness 0.3 mm in Example 3 vs. 1.2 mm in the traditional group).

[0110] In summary, Example 1 relies on the rapid antibacterial and anti-inflammatory synergy of erythromycin and forsythia; Example 2 shortens the time it takes for the drug to reach the lesion by optimizing the transdermal system; and Example 3 achieves "explosive sterilization" with ultra-high antibiotic concentration + stable excipients.

[0111] The core mechanisms for reducing recurrence: Myrrh promotes vascular remodeling (VEGF↑), Forsythia inhibits chronic inflammation (IL-6↓), and erythromycin reduces bacterial residuals; all three are essential. Single-ingredient preparations, due to their single action, are unable to interrupt the chain reaction of recurrence.

[0112] The key of transdermal technology:

[0113] Azone, nano-gel and pH-sensitive gel improve bioavailability from the perspectives of physical penetration enhancement, particle size control and intelligent release, respectively, which doubles the therapeutic effect of Example 2 at the same dose.

[0114] The formulation process allows for precise control of drug efficacy: The nano-sizing process in Example 2 maximizes the drug's specific surface area, breaking through the solubility bottleneck of traditional formulations. Carbomer's pH sensitivity enables precise drug release at the lesion site, avoiding the risk of systemic exposure. The combined use of DTA and antioxidants ensures the retention of high-concentration erythromycin activity during preparation and storage.

[0115] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. A fast-acting anti-inflammatory hemorrhoid ointment, characterized in that: include, The quick-acting anti-inflammatory hemorrhoid ointment comprises the following components in parts by mass: Forsythia suspensa 1-15g, 1-15 grams of borneol. Myrrh 1-15 grams, Erythromycin 1-15 grams.

2. The quick-acting anti-inflammatory hemorrhoid ointment according to claim 1, wherein: The weight ratio of Forsythia suspensa, borneol, myrrh and erythromycin is 8:5:6:

4.

3. The fast-acting anti-inflammatory hemorrhoid ointment according to claim 1, wherein: The invention also comprises auxiliary material matrix, wherein the matrix is one or more of vaseline, glycerin and liquid paraffin, accounting for 30-70% of the total weight.

4. The quick-acting anti-inflammatory hemorrhoid ointment according to claim 3, wherein: The matrix is also added with 1-3% of azone, a transdermal enhancer.

5. The method for preparing a fast-acting anti-inflammatory hemorrhoid ointment according to any one of claims 1 to 4, characterized in that: The following steps are involved: a. Crush the forsythia and myrrh into 80-120 mesh; b. Grind borneol into fine powder separately; c. Mix erythromycin and Chinese medicine powder, add molten matrix and stir; d. Homogenize and cool to form.

6. The method for preparing the quick-acting anti-inflammatory hemorrhoid ointment according to claim 5, wherein: In step c, the stirring temperature is 50-70° C. and the stirring time is 20-40 minutes.

7. The fast-acting anti-inflammatory hemorrhoid ointment according to claim 1, wherein: It further contains the preservative benzalkonium bromide 0.5-1.5%.

8. The fast-acting anti-inflammatory hemorrhoid ointment according to claim 1, wherein: Suitable for internal hemorrhoids, external hemorrhoids, mixed hemorrhoids and perianal infections.

9. The fast-acting anti-inflammatory hemorrhoid ointment according to claim 1, wherein: The erythromycin may be replaced by the equivalent antibiotics clarithromycin or azithromycin.

10. Use of the hemorrhoid ointment according to claim 1 in preparing a medicament for repairing anorectal surgery.

Images